← All trials
NCT05108012
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Apr 30, 2022
- First posted
- Nov 4, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Royan InstituteLead sponsor
- University of TehranCollaborator
- Tehran University of Medical ScienceStudy director
- Tehran University of Medical ScienceStudy chair
- Tehran University of Medical ScienceOverall official - principal investigator
- Tehran University of Medical ScienceOverall official - principal investigator
- Tehran University of Medical ScienceStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.